Literature DB >> 18446394

P846, a new gadolinium based low diffusion magnetic resonance contrast agent, in characterizing occlusive infarcts, reperfused ischemic myocardium and reperfused infarcts in rats.

Alexis Jacquier1, Matthew Bucknor, Loi Do, Philippe Robert, Claire Corot, Charles B Higgins, Maythem Saeed.   

Abstract

OBJECT: This study has two objectives: (1) to compare the kinetics of low diffusion P846 with Gd-DOTA using inversion recovery echo planar (IR-EPI) magnetic resonance (MR) imaging and (2) to determine the potential of P846 in defining myocardial viability in hearts subjected to various injuries using T1-weighted spin echo (T1-SE).
MATERIALS AND METHODS: Rats were subjected to (1) occlusive infarcts (n = 16), (2) reperfused ischemic injuries (n = 8) or (3) reperfused infarcts (n = 16). A dose of 0.05 mmol/kg P846 was compared to 0.1 mmol/kg Gd-DOTA. IR-EPI and T1-SE images were obtained during 60 min. T(1), DeltaR(1) and DeltaR(1) ratio were measured on IR-EPI. Infarct extents were evaluated on T1-SE and compared with histochemical staining.
RESULTS: Blood DeltaR(1) was higher at 5 min after P846 (6.36 +/- 0.32 s(-1)) than after Gd-DOTA (1.30 +/- 0.14 s(-1); P < 0.001). With P846, occlusive infarcts appeared as a hypoenhanced region surrounded by a hyperenhanced rim that lasted for 60 min. The increase in the DeltaR(1) ratio value was slower after P846 than with Gd-DOTA in the reperfused infarcts, suggesting low diffusion/convection of P846. Gd-DOTA homogenously enhanced both occlusive and reperfused infarcts at 30 min.
CONCLUSION: P846 provides better contrast and extended discrimination between occlusive and reperfused infarcts compared with Gd-DOTA. The gadolinium dose could be reduced with P846.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18446394     DOI: 10.1007/s10334-008-0112-8

Source DB:  PubMed          Journal:  MAGMA        ISSN: 0968-5243            Impact factor:   2.310


  35 in total

1.  Discrimination of myocardial acute and chronic (scar) infarctions on delayed contrast enhanced magnetic resonance imaging with intravascular magnetic resonance contrast media.

Authors:  Maythem Saeed; Oliver Weber; Randall Lee; Loi Do; Alastair Martin; David Saloner; Philip Ursell; Philippe Robert; Claire Corot; Charles B Higgins
Journal:  J Am Coll Cardiol       Date:  2006-10-31       Impact factor: 24.094

2.  Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA).

Authors:  Christoph U Herborn; Elmar Honold; Michael Wolf; Jörn Kemper; Sonja Kinner; Gerhard Adam; Jörg Barkhausen
Journal:  Invest Radiol       Date:  2007-01       Impact factor: 6.016

3.  Inversion recovery EPI of bolus transit in rat myocardium using intravascular and extravascular gadolinium-based MR contrast media: dose effects on peak signal enhancement.

Authors:  M F Wendland; M Saeed; K K Yu; T P Roberts; K Lauerma; N Derugin; J Varadarajan; A D Watson; C B Higgins
Journal:  Magn Reson Med       Date:  1994-09       Impact factor: 4.668

4.  An improved MR imaging technique for the visualization of myocardial infarction.

Authors:  O P Simonetti; R J Kim; D S Fieno; H B Hillenbrand; E Wu; J M Bundy; J P Finn; R M Judd
Journal:  Radiology       Date:  2001-01       Impact factor: 11.105

5.  Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function.

Authors:  R J Kim; D S Fieno; T B Parrish; K Harris; E L Chen; O Simonetti; J Bundy; J P Finn; F J Klocke; R M Judd
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

6.  Noninvasive assessment of myocardial stunning from short-term coronary occlusion using tagged magnetic resonance imaging.

Authors:  D L Kraitchman; H B Hillenbrand; I Oznur; J A Lima; E R McVeigh; E A Zerhouni; D A Bluemke
Journal:  J Cardiovasc Magn Reson       Date:  2000       Impact factor: 5.364

7.  Magnetic resonance characterization of the peri-infarction zone of reperfused myocardial infarction with necrosis-specific and extracellular nonspecific contrast media.

Authors:  M Saeed; G Lund; M F Wendland; J Bremerich; H Weinmann; C B Higgins
Journal:  Circulation       Date:  2001-02-13       Impact factor: 29.690

8.  Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I.

Authors:  Padma Kaul; Paul W Armstrong; Wei-Ching Chang; C David Naylor; Christopher B Granger; Kerry L Lee; Eric D Peterson; Robert M Califf; Eric J Topol; Daniel B Mark
Journal:  Circulation       Date:  2004-09-20       Impact factor: 29.690

9.  Case-control study of gadodiamide-related nephrogenic systemic fibrosis.

Authors:  Peter Marckmann; Lone Skov; Kristian Rossen; James Goya Heaf; Henrik S Thomsen
Journal:  Nephrol Dial Transplant       Date:  2007-05-04       Impact factor: 5.992

10.  Alterations in T1 of normal and reperfused infarcted myocardium after Gd-BOPTA versus GD-DTPA on inversion recovery EPI.

Authors:  M F Wendland; M Saeed; K Lauerma; N Derugin; J Mintorovitch; F M Cavagna; C B Higgins
Journal:  Magn Reson Med       Date:  1997-03       Impact factor: 4.668

View more
  2 in total

1.  Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights.

Authors:  Louke J Delrue; Veerle Casneuf; Nancy Van Damme; Peter Blanckaert; Marc Peeters; Wim P Ceelen; Philippe C O Duyck
Journal:  MAGMA       Date:  2011-05-13       Impact factor: 2.310

2.  Dynamic Contrast-Enhanced MRI Using a Macromolecular MR Contrast Agent (P792): Evaluation of Antivascular Drug Effect in a Rabbit VX2 Liver Tumor Model.

Authors:  Hee Sun Park; Joon Koo Han; Jeong Min Lee; Young Il Kim; Sungmin Woo; Jung Hwan Yoon; Jin-Young Choi; Byung Ihn Choi
Journal:  Korean J Radiol       Date:  2015-08-21       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.